Overview

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation following chemotherapy in treating patients with acute myeloid leukemia in second remission.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborator:
National Cancer Institute (NCI)
Treatments:
Busulfan
Cytarabine
Etoposide
Methotrexate
Criteria
DISEASE CHARACTERISTICS: Diagnosis of acute myeloid leukemia (AML) in second complete
remission (CR) for 30 days to less than 1 year before study entry Second CR defined by the
following: Neutrophil count at least 1,000/mm3 Platelet count at least 100,000/mm3 Normal
bone marrow morphology with no excess blasts (greater than 5%) No myelodysplasia No
extramedullary or CNS leukemia Initial diagnosis of de novo AML (M0-M7) No prior
myelodysplasia No myeloproliferative disease No secondary AML Cytogenetics not required No
cytogenetic evidence of persistent leukemia if cytogenetics performed

PATIENT CHARACTERISTICS: Age: 15 to 69 Hematopoietic: See Disease Characteristics
Granulocyte count at least 1,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL AST less than 3
times normal Alkaline phosphatase less than 3 times normal No cirrhosis or chronic
hepatitis Biopsy required if chronic liver disease suspected (history of alcohol abuse or
possible hepatitis) Renal: Creatinine less than 2.0 mg/dL Other: Not pregnant or nursing
Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow/stem cell transplantation
Chemotherapy: Prior non-ablative chemotherapy at initial diagnosis, during initial
remission, or as reinduction therapy (to produce current second remission) allowed At least
4 weeks since hospital discharge after reinduction therapy Endocrine therapy: Not specified
Radiotherapy: Not specified Surgery: Not specified Other: No prior post-remission therapy
for second remission